Valeant looks to sell billions in assets to cut debt, stock soars
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Valeant Pharma (VRX) Pushes to Session Highs
August 9, 2016 2:26 PM EDTValeant Pharma (NYSE: VRX) continues to push to the highs of the session following results and better-than-expected guidance. Shares are up 23.5% on volume that is running 5x the norm. Short covering is seen as a contributor to today's upside.
... MoreValeant (VRX) Provides Plenty to Support Bullish Thesis - Guggenheim
August 9, 2016 10:25 AM EDTGuggenheim analyst Louise Chen reiterated a Buy rating and $55 price target on Valeant Pharmaceuticals (NYSE: VRX) following a Q2 miss but reaffirmed '16 EPS guidance.
Chen notes, "VRX has noted since its 1Q16 call that it expects the business to recover in 2H16 as it moves past the issues with its derm business, and achieved its objective to report a 40%/60% earnings split between 1H16/2H16. Therefore, our investment thesis remains intact, and we continue to believe that VRX's growth... More
